Dr. Racette is theVice Chairman in charge of Clinical Affairs

My specialty is movement disorders. In addition, I treat a large number of people with spasticity. I perform botulinum toxin injections for a variety of conditions. Common conditions treated in my office include:
Parkinson's disease
Huntington's disease
Dystonia
Ataxia
Hemifacial spasm
Tourette's Syndrome
Tremor
Spasticity

My research interests include the genetics of Parkinson's disease (especially in people of Amish ancestry), Welding related Parkinson's disease, and investigations into new medications for Parkinson's disease, dystonia, and Huntington's disease.

Medical Training

Dr. Racette received his A.B. in 1988 in Molecular Biology from Princeton University. He graduated from Northwestern University Medical School in 1992. Following an internship at Northwestern Memorial Hospital in Chicago, IL, he completed residency training in Neurology at Barnes Hospital (Washington University School of Medicine). He completed a fellowship in Movement Disorders at Washington University School of Medicine in 1998 and was appointed to the faculty as an Assistant Professor of Neurology in 1998. Dr. Racette is a member of the American Academy of Neurology, the Movement Disorders Society, the Parkinson's Study Group, and the Huntington's Study Group. He serves on the medical advisory board of the St. Louis chapter of the American Parkinson's Disease Association the Missouri chapter of the Dystonia Medical Research Foundation. In addition, he serves as co-medical director of the Huntington's Disease Society of America (St. Louis Chapter). Licensure Diplomate, National Board of Medical Examiners Missouri Board of the Healing Arts Diplomate, American Board of Neurology & Psychiatry.

Selected Publications

Racette BA, Rundle M, Parsian A, Perlmutter JS. Evaluation of a Screening Questionnaire for Genetic Linkage Studies of Parkinson's Disease. American Journal of Medical Genetics (Neuropsychiatric section) 1999;88:539-543.

Racette B, Gokden M, Tychsen L, Perlmutter J. Convergence insufficiency in idiopathic Parkinson's disease responsive to levodopa. Strabismus. 1999;7:3,169-174.

Racette BA, McGee-Minnich L, Perlmutter JS. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation. Clinical Neuropharmacology.1999;22:6,337-339.

Revilla FJ, Racette BA, Perlmutter JS. Chorea and Jaw Opening Dystonia as a Manifestation of NeuroBehcet's Syndrome. Movement Disorders. Movement Disorders 2000;l15(4):740-744.

Racette BA, McGee-Minnich L, Moerlein SM, Mink JW, Perlmuter JS. Welding Related Parkinsonism: Clinical features, Treatment, and Pathophysiology. Neurology 2001;56:8-13.

Racette BA, Dowling J, Randle J, Mink JW. Thalamic Stimulation for Primary Writing Tremor. J Neurol 2001;248:380-382.

Racette BA, Rich KM, Randle J, Mink JW. Ipsilateral Thalamic Stimulation After Thalamotomy For Essential Tremor. Stereo Neurosurg 2000;75:155-159.

Racette BA, Perry A, D'Avossa G, Perlmutter JS. Late Onset Hallervorden-Spatz Syndrome: Expanding the Clinical Spectrum. Movement Disorders 2001; 16(6):1148-1152.

Racette BA, Hartlein J, Mink JW, Perlmutter JS. PD Related Mood Fluctuations: Clinical features and Co-morbidities. J Neuropsychiatry Clin Neurosci 2002;14(4):438-442.

Racette BA, Rundle M, Wang JC, Goate A. Saccone NL, Farrer M, Lincoln S, Hussey J, Lin J, Suarez B, Parsian A, Perlmutter JS. A Multi-incident, Old-Order Amish family with PD. Neurology 2002; 58: 568_574.

Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson's disease and apolipoprotein E: Possible association with dementia but not age of onset. Genomics. 2002;79(3):458_61.

Racette BA, Stambuk M, Perlmutter JS. Secondary Non-responsiveness to New Bulk Botulinum Toxin A (BCB2024). Movement Disorders 2002;17(5)1098-1100.

Racette BA, Lopate G, Good L, Sagitto S, Perlmutter JS. Ptosis as a remote effect of therapeutic botulinum toxin B injection. Neurology 2002;59,1445-1447.

Racette BA, Good L, Sagitto S, Perlmutter JS. Botulinum toxin B reduces sialorrhea in parkinsonism. Mov Disord 2003;18(9):1059_61.

Parsian A, Racette B, Zhang ZH, Rundle MR, Perlmutter JS. Association studies of Parkinson's disease subgroups and monoamine oxidases A and B. Genomics 2004; 83(3):454-60.

Hou C, Schlaggar, BS, Racette BA. Dystonia due to ring chromosome 21. Mov Disorders Mov Disord. 2003;18(12):1547-9.

Parsian, AP, Sinha R, Racette BA, Zhao, JH, Perlmutter, JS. Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease. Parkinsonism and Related Disorders 2004 Jun;10(4):213:9.

Karamohamed S, DeStefano AL, Wilk JB, Shoemaker CM, Golbe LI, Mark MH,. Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, GF, Stacy M, Saint_Hilaire M, Feldman RG, Sullivan KM, Xu G, Watts R, Growdon J, Lew M, Waters C, Vieregge P, Pramstaller PP, Klein C, Racette BA, Perlmutter JS, Parsian A, Singer C, Montgomery E, Baker K, Gusella JF, Fink SJ, Myers RH, Herbert A. A haplotype at the PARK3 locus influences onset age for Parkinson's disease: The GenePD study. Neurology 2003;61:1557.

Racette BA, Esper GJ, Antenor J, Black K, Burkey A, Moerlein SM, Videen TO, Kotagal V, Ojemann J, Perlmutter JS. Pathophysiology of Parkinsonism due to Hydrocephalus. J Neurol Neurosurg Psychiatry 2004;75(11):1617-1619.

Pastor P, Ezquerra M., Perez JC., Chakraverty S., Norton J., Racette B, Perlmutter JS, McKeel D, Tolosa E., Goate AM. Novel haplotypes in 17q21 are associated with progressive supranuclear palsy. Ann. Neurol 2004;56(2):249-258.

Racette BA, Antenor, J, McGee-Minnich, L, Moerlein, SM, Videen TO, Kotagal V, Perlmutter JS.[18F]FDOPA PET and clinical features in parkinsonism due to manganism. Movement Disorders 2005;20(4):492-496.

Smith JL, Ju JS, Saha BM, Racette BA, Fisher JS. Levodopa with Carbidopa Diminishes Glycogen Concentration, Glycogen Synthase Activity, and insulin-stimulated glucose transport in rat skeletal muscle. J Appl Physiol 2004;97(6):2339-2346.

Racette BA, Tabbal SD, Jennings D, Good LM, Perlmutter JS, Evanoff BA.. Prevalence of Parkinsonism and relationship to exposure in a Large Sample of Alabama Welders. Neurology 2005;64:230-235.

Racette BA, Tabbal SD, Jennings D, Good LM, Perlmutter JS, Evanoff BA. A Rapid Method for Mass Screening for Parkinsonism. Neurotoxicology. In press.

Racette BA, Good LM, Antenor, J, McGee-Minnich, L, Moerlein, SM, Videen TO, Perlmutter JS. [18F]FDOPA PET as an Endophenotype for PD Linkage. American Journal of Medical Genetics (Neuropsychiatric section) In press.

Parsian, AP, Sinha R, Racette BA, Zhao, JH, Perlmutter, JS. Prevalence of parkin gene mutations and variations in IPD. Parkinsonism and Related Disorders. In press.

Karamohamed S, DeStefano AL, Wilk JB, Shoemaker CM, Golbe LI, Mark MH,. Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, GF, Stacy M, Saint_Hilaire M, Feldman RG, Sullivan KM, Xu G, Watts R, Growdon J, Lew M, Waters C, Vieregge P, Pramstaller PP, Klein C, Racette BA, Perlmutter JS, Parsian A, Singer C, Montgomery E, Baker K, Gusella JF, Fink SJ, Myers RH, Herbert A. Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Movement Disorders. In press.